Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NVAX 
Novavax Inc (NVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NVAX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 3 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.62% | Avg. Invested days 20 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.21B USD | Price to earnings Ratio 3.36 | 1Y Target Price 12.5 |
Price to earnings Ratio 3.36 | 1Y Target Price 12.5 | ||
Volume (30-day avg) 7 | Beta 2.5 | 52 Weeks Range 5.01 - 15.22 | Updated Date 08/29/2025 |
52 Weeks Range 5.01 - 15.22 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.06 | Actual 0.62 |
Profitability
Profit Margin 39.2% | Operating Margin (TTM) 44.17% |
Management Effectiveness
Return on Assets (TTM) 14.52% | Return on Equity (TTM) -898.2% |
Valuation
Trailing PE 3.36 | Forward PE 7.86 | Enterprise Value 847342069 | Price to Sales(TTM) 1.12 |
Enterprise Value 847342069 | Price to Sales(TTM) 1.12 | ||
Enterprise Value to Revenue 0.79 | Enterprise Value to EBITDA 1.71 | Shares Outstanding 162422000 | Shares Floating 136723292 |
Shares Outstanding 162422000 | Shares Floating 136723292 | ||
Percent Insiders 8.76 | Percent Institutions 58.29 |
Upturn AI SWOT
Novavax Inc
Company Overview
History and Background
Novavax Inc. was founded in 1987. Initially focused on developing new vaccines using innovative technologies, the company pivoted to focus on recombinant nanoparticle vaccine technology. A significant milestone was the development and approval of their COVID-19 vaccine, Nuvaxovid.
Core Business Areas
- Vaccine Development and Manufacturing: Novavax's primary focus is on researching, developing, and manufacturing vaccines, particularly recombinant nanoparticle vaccines.
Leadership and Structure
Stanley C. Erck is the current President and CEO. The company operates with a functional organizational structure, with departments dedicated to research and development, manufacturing, commercial operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Nuvaxovid (COVID-19 Vaccine): Nuvaxovid is Novavax's protein-based COVID-19 vaccine. Market share is still developing and varies by region. Competitors include Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The vaccine market is a large and growing market driven by the need to combat infectious diseases. It's dominated by established players and characterized by high regulatory hurdles and significant R&D investments.
Positioning
Novavax is a relatively smaller player in the vaccine market, attempting to compete with larger, more established companies. Its COVID-19 vaccine has been a key product, and its competitive advantage lies in its protein-based technology and perceived safety profile (lower instances of side effects vs mRNA).
Total Addressable Market (TAM)
The global vaccine market is expected to reach hundreds of billions of dollars. Novavax's positioning is dependent on securing future contracts and indications with the COVID vaccine and expanding into other vaccines.
Upturn SWOT Analysis
Strengths
- Protein-based vaccine technology
- Potentially fewer side effects compared to mRNA vaccines
- Established manufacturing partnerships
Weaknesses
- Relatively smaller size compared to competitors
- Dependent on COVID-19 vaccine demand
- Past manufacturing and regulatory delays
- Limited portfolio beyond Covid Vaccine
Opportunities
- Expansion into other vaccines (e.g., influenza)
- Developing combination vaccines (e.g., COVID-19/influenza)
- Securing more government contracts
- Expansion into new markets
Threats
- Competition from larger vaccine manufacturers
- Evolving COVID-19 variants
- Changes in government vaccine policies
- Negative perception due to past delays
Competitors and Market Share
Key Competitors
- Pfizer (PFE)
- Moderna (MRNA)
- Johnson & Johnson (JNJ)
Competitive Landscape
Novavax faces stiff competition from larger, more established players. Its protein-based vaccine technology provides a potential advantage, but its lack of a developed pipeline is a disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by the COVID-19 pandemic and the development and approval of Nuvaxovid.
Future Projections: Future growth is uncertain and depends on future COVID-19 variant changes and contracts along with the successful development of the other vaccines.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, securing new government contracts, and pursuing regulatory approvals in new markets.
Summary
Novavax is a vaccine company facing significant competition in the vaccine market. Nuvaxovid has provided revenue, but the company needs to develop and commercialize additional products to diversify its revenue stream. The company's future depends on securing more contracts, managing manufacturing costs, and overcoming regulatory hurdles. Volatility is expected.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novavax Inc
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 1995-12-05 | President, CEO & Director Mr. John Charles Jacobs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 952 | Website https://www.novavax.com |
Full time employees 952 | Website https://www.novavax.com | ||
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.